EPIS_B: Strong sales growth and improved losses as US expansion and cost savings accelerate

About this update from Episurf Medical Ab Class B

Episurf Medical delivered 45% sales growth and improved losses year-over-year, driven by rapid US expansion and cost-saving measures, including pausing the EPIC-Knee trial. A SEK 90m rights issue bolstered liquidity, with a sharpened focus on US commercialization.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Episurf Medical Ab Class B